Related Experiment Video

Updated: Jul 13, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.7K

Sarcoma: Cardiovascular and Oncologic Considerations: JACC: CardioOncology State-of-the-Art Review

Daniel S Lefler1, Elise F Nassif Haddad2, Anju Nohria3

  • 1Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

JACC. Cardiooncology
|November 17, 2025
PubMed

Insights

This review discusses cardiac sarcomas and the cardiotoxicity risks associated with sarcoma treatments, including anthracyclines. It emphasizes risk modification strategies and cardiac surveillance for patients undergoing sarcoma therapy.

Area of Science:

  • Oncology
  • Cardiology
  • Tumor Biology

Background:

  • Sarcomas are rare connective tissue tumors with diverse histologic subtypes.
  • Cardiac sarcomas, including angiosarcoma and leiomyosarcoma, present unique challenges.
  • Systemic therapies for sarcomas frequently cause cardiotoxicity.

Purpose of the Study:

  • To review the unique aspects of cardiac sarcoma care.
  • To discuss cardiovascular side effects of systemic sarcoma agents.
  • To outline cardiac surveillance strategies for sarcoma patients.

Main Methods:

  • Literature review of cardiac sarcomas and treatment-related cardiotoxicity.
  • Analysis of cardiovascular risks associated with common sarcoma therapies.
  • Examination of risk mitigation and surveillance protocols.

Main Results:

  • Cardiac sarcomas require multimodality treatment approaches.
  • Anthracyclines are a cornerstone of sarcoma treatment, necessitating cardiotoxicity risk modification.
  • Various systemic agents used in sarcoma treatment carry significant cardiovascular risks.

Conclusions:

  • Effective management of cardiac sarcomas involves understanding tumor biology and treatment complexities.
  • Proactive cardiac surveillance and risk mitigation are essential for sarcoma patients.
  • Multidisciplinary care is crucial for optimizing outcomes in patients with cardiac sarcomas.

Keywords:
anthracyclinescardiac tumorschemotherapy complicationsprimary cardiac sarcomapulmonary artery sarcomasarcomatyrosine kinase inhibitors

More Related Videos

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.6K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K

Related Concept Videos

Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...